INS and metabolic dysfunction-associated steatohepatitis: A multicenter, double-blind, placebo-controlled clinical trial of NASH patients without cirrhosis indicated that OCA increased glucose levels and insulin resistance (Neuschwander-Tetri et al., 2015).